

**Table e-3: Analysis in the complete sample and after splitting in the “old” and the “new” sample**

“all”: all patients; “oldS”: patients already included in the previous GWAS<sup>1</sup>; “newS”: patients not included in the previous GWAS.

CHR	BP [GRCh38]	dbSNP ID	MAF affected	MAF control	OR_all [95% CI]	P all	Gene	OR oldS	P oldS	OR newS	P newS
15	100978492	rs10902588	0.33	0.18	2.24 [1.70-2.95]	1.18e-08	LRRK1	2.43	1.13e-06	2.05	8.57e-05
15	100985970	rs2412001	0.34	0.19	2.18 [1.66-2.85]	1.39e-08	LRRK1	2.29	3.30e-06	2.08	3.73e-05
15	100996156	rs4995826	0.38	0.22	2.14 [1.64-2.78]	1.53e-08	LRRK1	2.46	3.29e-07	1.85	3.59e-04
15	100996211	rs4352030	0.38	0.22	2.14 [1.64-2.78]	1.53e-08	LRRK1	2.46	3.29e-07	1.85	3.59e-04
15	100996820	rs966292	0.38	0.22	2.14 [1.64-2.78]	1.53e-08	LRRK1	2.46	3.29e-07	1.85	3.59e-04
15	100998427	rs66793839	0.38	0.22	2.14 [1.64-2.78]	1.53e-08	LRRK1	2.46	3.29e-07	1.85	3.59e-04
15	100986608	rs11636885	0.32	0.18	2.19 [1.66-2.89]	2.66e-08	LRRK1	2.30	4.97e-06	2.08	5.58e-05
15	100996725	rs966293	0.32	0.18	2.19 [1.66-2.89]	2.87e-08	LRRK1	2.33	3.76e-06	2.06	7.96e-05
15	101000513	rs55785108	0.32	0.18	2.19 [1.66-2.89]	2.87e-08	LRRK1	2.33	3.76e-06	2.06	7.96e-05
15	100980449	rs12442816	0.32	0.18	2.17 [1.65-2.86]	3.60e-08	LRRK1	2.27	6.68e-06	2.07	6.33e-05
11	47244920	rs75393320	0.29	0.16	2.20 [1.66-2.92]	3.78e-08	ACP2	2.60	1.37e-07	1.90	1.13e-03
11	47259211	rs11039155	0.29	0.16	2.20 [1.66-2.92]	3.78e-08	NR1H3	2.60	1.37e-07	1.90	1.13e-03
15	101003755	rs55759655	0.34	0.19	2.12 [1.62-2.78]	3.96e-08	LRRK1	2.20	9.55e-06	2.06	4.70e-05

## Reference

1. Mueller SH, Farber A, Pruess H, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. *Ann Neurol.* 2018;83(4):863-869.